← All compounds
Well Researched

CJC-1295 (no DAC) / Ipamorelin Protocol

Mod GRF 1-29 + Ipamorelin | Pulsatile Growth Hormone Optimization

A combination protocol using CJC-1295 without DAC (also known as Mod GRF 1-29) and Ipamorelin through complementary receptor mechanisms. CJC-1295 without DAC has a short half-life of 30 minutes to 2 hours, enabling pulsatile GH release that mimics natural physiology. Ipamorelin provides selective GH release without affecting cortisol, ACTH, or prolactin. Note: This protocol uses the no-DAC version specifically for pulsatile release patterns.

Daily dose

200-300 mcg each peptide

Frequency

Once or twice daily

Cycle length

8-12 weeks

Storage

2-8°C

Administration

injectable

Interactions

Monitor Combination
MK-677 — Both affect GH pathways. Monitor for excessive GH elevation and potential insulin sensitivity changes with combined use.
Compatible
BPC-157 — No known interactions. Different mechanisms - GH optimization versus direct tissue repair signaling.
Monitor Combination
Insulin — Growth hormone affects insulin sensitivity. Diabetic users require blood glucose monitoring and potential insulin dose adjustments.
Avoid Combination
Synthetic HGH — Redundant mechanisms may cause excessive GH levels and suppress natural pulsatile release patterns.
Requires Timing
Thyroid Medications — Space thyroid medications 4+ hours from GH secretagogues due to potential absorption and metabolic interactions.
Use Caution
Corticosteroids — Corticosteroids can blunt GH response. May require higher doses or alternative timing when used together.

Research studies

CJC-1295 with DAC Clinical Efficacy - Teichman et al. (2006)

Human | 30-60 mcg/kg | 28-49 days | CJC-1295 WITH DAC version

Note: This landmark study used CJC-1295 WITH DAC (5.8-8.1 day half-life), not the no-DAC version used in CJC/IPA protocols. Included for reference on the GHRH analog mechanism, but pharmacokinetics differ significantly from Mod GRF 1-29.

View study →

Modified GRF 1-29 Pharmacokinetics

Human | Various doses | Short-acting GHRH analog

CJC-1295 without DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes to 2 hours due to lack of albumin-binding DAC. This short duration enables pulsatile GH release patterns preferred for combination protocols with GHRPs like Ipamorelin.

GH Pulsatility Preservation - Ionescu & Frohman (2006)

Human | Continuous monitoring | 14 days | Maintained natural rhythm

Demonstrated CJC-1295 preserves pulsatile GH secretion while increasing basal levels 7.5-fold.

View study →

GHS Receptor Desensitization - Camiña et al. (2004)

Cell culture | GHSR1a receptors | ~6 hour recovery time after stimulation

Demonstrated rapid GHS receptor desensitization within minutes, with full recovery requiring approximately 6 hours. Supports spacing doses for sustained responsiveness.

View study →

GHRH-GHS Receptor Interaction - Cunha & Mayo (2002)

Cell culture | Transfected receptors | Enhanced cAMP production

Cellular study showing potentiation of GHRH-induced signaling when GHS receptors also present.

View study →

Ipamorelin Selectivity - Raun et al. (1998)

Multiple species | Various doses | Selective GH release without ACTH/cortisol effects

Landmark study establishing Ipamorelin as first selective GHS with no effects on stress hormones even at 200x effective dose.

View study →

Related compounds

CJC-1295 (without DAC)IpamorelinSermorelinTesamorelin